Vanda Pharmaceuticals Secures FDA Approval for BYSANTI™ in Bipolar I and Schizophrenia

summarizeSummary

Vanda Pharmaceuticals announced FDA approval for BYSANTI™ (milsaperidone), a new chemical entity, for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia in adults, with commercial launch expected in Q3 2026.

check_boxKey Events

• FDA Approves BYSANTI™ (milsaperidone)

  The U.S. Food and Drug Administration (FDA) has approved BYSANTI™ (milsaperidone) tablets, a new chemical entity (NCE), for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia in adults.

• Commercial Launch Expected Q3 2026

  Vanda Pharmaceuticals anticipates commercial availability of BYSANTI™ in the third quarter of 2026.

• Long-Term Market Exclusivity

  BYSANTI™ marketing exclusivity is expected to be protected by regulatory data exclusivity and issued US patents, with the latest expiring in 2044, providing a robust foundation for long-term revenue.

• Second New Drug Approval in Two Months

  This marks the second new drug approval for Vanda in less than two months, following the approval of NEREUS™ in December 2025, indicating strong pipeline execution amidst recent financial and regulatory challenges.

auto_awesomeAnalysis

This FDA approval for BYSANTI™ (milsaperidone) is a critical positive development for Vanda Pharmaceuticals, especially following recent financial losses and the FDA's rejection of its sNDA for HETLIOZ. As a new chemical entity (NCE) approved for two significant psychiatric conditions, bipolar I disorder and schizophrenia, BYSANTI™ represents a substantial new revenue opportunity. The anticipated commercial launch in Q3 2026 and patent exclusivity extending to 2044 provide a long runway for growth and could significantly improve the company's financial outlook and investor sentiment, which has been challenged by recent setbacks.